Role of vascular disorders in lung injury in patients with rheumatoid arthritis

Introduction. The incidence of respiratory system involvement in patients with rheumatoid arthritis (RA) has currently increased; thereby new diagnostic methods have been developed actively. Meanwhile role of vascular disorders in pathogenesis of lung injury is almost unknown and single-photon emission computed tomography (SPECT) isn't used as method of lung assessment in RA. The detector of endothelial glycocalyx damage syndecan-1 is little known but potentially perspective serum marker of lung injury in RA. Objective. The purpose of the study was to investigate the role of vascular disorders in lung injury in patients with RA. Materials and methods. 61 patients with RA without comorbid lung diseases were enrolled in the study. Control group consisted of 26 healthy persons. Patients underwent survey and physical examination, high-resolution computed tomography (HRCT) and SPECT of the lungs and pulmonary function tests (PFTs). Also serum levels of rheumatoid factor (RF), anti-cyclic citrullinated peptide antibodies (ACCP) and syndecan-1 were measured. Results. All patients developed microcirculation impairment on SPECT. Vascular disorders were according to changes of lung structure detected by HRCT (r = 0.434; p = 0.044). Areas of hypoperfusion matched with ground glass opacities, lung fibrosis, branching linear structures and airway obstruction on HRCT-SPECT fusion scans. Syndecan-1 level was higher in patients with RA compared with healthy controls (р = 0.019). Conclusion. Vascular disorders are important in pathogenesis of lung injury in RA, and SPECT has high sensitivity in lung assessment. Perfusion impairment in lungs correlates with syndecan-1 level, thus syndecan-1 could be used as marker of lung injury in RA thereafter.

ревматоидный артрит, поражение легких, сосудистые нарушения, повреждение эндотелия, компьютерная томография, однофотонная эмиссионная компьютерная томография, синдекан-1, rheumatoid arthritis, lung injury, vascular disorders, endothelial damage, computed tomography, single-photon emission computed tomography, syndecan-1

1. Амосов В.И., Сперанская А.А., Золотницкая В.П. Возможности лучевой диагностики в оценке сосудистых нарушений у больных с диссеминированными процессами в легких // Российский электронный журнал лучевой диагностики. 2011. Т. 1. № 2 (2). С. 36-46.

2. Бестаев Д.В., Божьева Л.А., Волков А.В. и др. Субклиническая форма интерстициального поражения легких при ревматоидном артрите // Клиницист. 2015. № 1. С. 30-36.

3. Лукина О.В., Амосов В.И., Золотницкая В.П. и др. Лучевая диагностика нарушений кровообращения у больных хронической обструктивной болезнью легких различных фенотипов // Лучевая диагностика и терапия. 2013. № 4(4). С. 88-94.

4. Карамышева А.Ф. О новых диагностических возможностях CD138 (синдекана-1) при множественной миеломе // Успехи молекулярной онкологии. 2015. Т. 2. № 3. С. 43-50.

5. Шеянов М.В., Щедрина И.С. Влияние поражений легких и нижних дыхательных путей на качество жизни пациентов с ревматоидным артритом // Вестник межнационального центра исследования качества жизни. 2014. № 23-24. С. 24-33.

6. Bagnato G., Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases // Eur Respir Rev. 2015. № 24(135). Р. 102-14. doi: 10.1183/09059180.00003214.

7. Cordier J.F. Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis // Thorax. 2007. № 62(7). Р. 638-649. doi: 10.1136/thx.2004.031005.

8. Doyle T.J., Patel A.S., Hatabu H. et al. Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers // Am J Respir Crit Care Med. 2015. № 191(12). Р. 1403-1412. doi: 10.1164/rccm.201411-1950OC.

9. Florian J.A., Kosky J.R., Ainslie K. et al. Heparan sulfate proteoglycan is a mechanosensor on endothelial cells // Circ Res. 2003. № 93(10). Р. 136-142.

10. Gochuico B.R., Avila N.A., Chow C.K. et al. Progressive preclinical interstitial lung disease in rheumatoid arthritis // Arch Intern Med. 2008. № 168(2). Р. 159-166. doi: 10.1001/archinternmed.2007.59.

11. Gotte M., Echtermeyer F. Syndecan-1 as a regulator of chemokine function // Scientific World Journal. 2003. № 3. Р. 1327-1331. doi: 10.1100/tsw.2003.118.

12. Kliment C.R., Englert J.M., Gochuico B.R. et al. Oxidative stress alters syndecan-1 distribution in lungs with pulmonary fibrosis // J Biol Chem. 2009. № 284(6). Р. 3537-3545. doi: 10.1074/jbc.M807001200.

13. Miranda C.H., de Carvalho Borges M., Schmidt A. et al. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome // Atherosclerosis. 2016. № 247. Р. 184-188. doi: 10.1016/j.atherosclerosis.2016.02.023.

14. Mori S., Koga Y., Sugimoto M. Small airway obstruction in patients with rheumatoid arthritis // Mod Rheumatol. 2011. № 21(2). Р. 164-173. doi: 10.1007/s10165-010-0376-5.

15. Olson A.L., Swigris J.J., Sprunger D.B. et al. Rheumatoid arthritis-interstitial lung disease associated mortality // Am J Respir Crit Care Med. 2011. № 183(3). Р. 372-378. doi: 10.1164/rccm.201004-06220C.

16. Paulin F., Doyle T.J., Fletcher E.A. et al. Rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonaryfibrosis: shared mechanistic and phenotypic traits suggest overlapping disease mechanisms // Rev Invest Clin. 2015. № 67(5). Р. 280-286.

17. Perry E., Kelly C., Eggleton P et al. The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury? // Rheumatology (Oxford). 2014. № 53 (11). Р. 1940-1950. doi: 10.1093/rheumatology/keu195.

18. Stepp M.A., Pal-Ghosh S., Tadvalkar G., Pajoohesh-Ganji A. Syndecan-1 and its expandingl of contacts // Adv Wound Care (New Rochelle). 2015. № 4(4). P. 235-249.

19. Tang G.L., Weitz K. Impaired arteriogenesis in syndecan-1(-/-) mice // J Surg Res. 2015. №193(1). Р. 22-27. doi: 10.1016/j.jss.2014.08.002.

20. Teng Y.H., Aquino R.S., Park P.W. Molecular functions of syndecan-1 in disease // Matrix Biol. 2012. № 1. Р. 3-16. doi: 10.1016/j.matbio.2011.10.001.

21. Torres Filho I.P., Torres L., Salgado C., Dubick M.A. Plasma syndecan-1 and heparan sulfate correlate with microvascular glycocalyx degradation in hemorrhaged rats after different resuscitation fluids // Am J Physiol Heart Circ Physiol. 2016. № 310(11). Р. 1468-1478. doi: 10.1152/ ajpheart.00006.2016.

22. Yablecovitch D., Stein A., Shabat-Simon M. et al. Soluble syndecan-1 levels are elevated in patients with inflammatory bowel disease // Dig Dis Sci. 2015. № 60(8). Р. 2419-2426. doi: 10.1007/s10620-015-3589-9.

23. Wu C.Y., Asano Y., Taniguchi T. et al. Serum level of circulating syndecan-1: A possible association with proliferative vasculopathy in systemic sclerosis // J Dermatol. 2016. № 43(1). Р. 63-66. doi: 10.1111/1346-8138.12986.